Singapore, 9 September 2021: A globally regarded sarcoma therapy that has been shown to improve progression free survival1 is now being re-introduced in key regions of South-East Asia by independent pharmaceutical company Specialised Therapeutics Asia (STA). The compound YONDELIS® (trabectedin) will be available to advanced sarcoma patients via their treating oncologists in Singapore, Malaysia and
